Linical Co Ltd
TSE:2183

Watchlist Manager
Linical Co Ltd Logo
Linical Co Ltd
TSE:2183
Watchlist
Price: 330 JPY
Market Cap: 7.5B JPY
Have any thoughts about
Linical Co Ltd?
Write Note

Linical Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Linical Co Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Linical Co Ltd
TSE:2183
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CMIC Holdings Co Ltd
TSE:2309
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Chiome Bioscience Inc
TSE:4583
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Medinet Co Ltd
TSE:2370
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CellSource Co Ltd
TSE:4880
Depreciation & Amortization
-ÂĄ25.5m
CAGR 3-Years
-47%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
WDB coco Co Ltd
TSE:7079
Depreciation & Amortization
-ÂĄ7.7m
CAGR 3-Years
-46%
CAGR 5-Years
-77%
CAGR 10-Years
N/A
No Stocks Found

Linical Co Ltd
Glance View

Market Cap
7.5B JPY
Industry
Life Sciences Tools & Services

Linical Co., Ltd. engages in pharmaceutical contract research projects providing consulting, monitoring, and quality control services to pharmaceutical companies. The company is headquartered in Osaka, Osaka-Fu and currently employs 845 full-time employees. The company went IPO on 2008-10-27. The firm operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

Intrinsic Value
1 017.89 JPY
Undervaluation 68%
Intrinsic Value
Price

See Also

Back to Top